Search by drug, manufacturer, or indication

Displaying 841 - 850 of 1165

Opdivo (nivolumab)

Status:

Negotiations were not pursued

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Hepatocellular Carcinoma (HCC) in adults after prior therapy

Last updated January 29, 2019

Faslodex (fulvestrant)

Status:

Concluded without agreement

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Breast Cancer, Locally Advanced or Metastatic

Last updated January 29, 2019

Bavencio (avelumab)

Status:

Concluded with an LOI

Manufacturer:

EMD Serono Canada, a division of EMD Inc.

Indication:

Metastatic Merkel Cell Carcinoma

Last updated January 17, 2019

Blincyto (blinatumomab)

Status:

Concluded with an LOI

Manufacturer:

Amgen Canada Inc.

Indication:

Acute Lymphoblastic Leukemia (ALL)

Last updated January 15, 2019

Blincyto (blinatumomab)

Status:

Concluded with an LOI

Manufacturer:

Amgen Canada Inc.

Indication:

Acute Lymphoblastic Leukemia (ALL), Pediatric

Last updated January 15, 2019

Perjeta/Herceptin (pertuzumab/trastuzumab)

Status:

Negotiations were not pursued

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Early Breast Cancer

Last updated December 28, 2018

Maviret (glecaprevir/pibrentasvir)

Status:

Concluded with an LOI

Manufacturer:

AbbVie Corporation

Indication:

Chronic Hepatitis C

Last updated December 19, 2018

Siliq (brodalumab)

Status:

Concluded with an LOI

Manufacturer:

Valeant Canada

Indication:

Psoriasis, moderate to severe plaque

Last updated December 14, 2018

Rexulti (brexpiprazole)

Status:

Concluded with an LOI

Manufacturer:

Otsuka Canada Pharmaceutical Inc.

Indication:

Schizophrenia

Last updated December 14, 2018

Alecensaro (alectinib)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Non-Small Cell Lung Cancer (First Line)

Last updated December 11, 2018